QSAM BIOSCIENCES INC - QSAM STOCK NEWS

Goldman Small Cap Research has published a new report on QSAM Biosciences, Inc. (OTCQB:QSAM), focusing on its innovative CycloSam® radiopharmaceutical therapy for treating bone cancer. The report emphasizes QSAM's promising market potential, addressing a $20 billion opportunity with potential indications such as osteosarcoma and metastatic bone cancers. QSAM has 8 patents granted and several designations, highlighting its competitive positioning. The company has recently completed enrollment for a Phase 1 study of CycloSam, with preliminary safety data expected soon. The report outlines a 12-month price target based on market comparisons.

QSAM Biosciences has completed the enrollment of the first cohort in its Phase 1 clinical trial for CycloSam®, a radiopharmaceutical aimed at treating metastatic bone cancer. The trial assesses the maximum tolerated dose and early safety signals of CycloSam®, with results indicating positive early outcomes. The next cohort, receiving a 50% higher dosage, is set to begin in early Q2 2023. This trial addresses a significant unmet medical need for patients with bone cancer, including those with metastatic breast cancer. The company aims to advance CycloSam® as a treatment option amid limited existing alternatives for female patients.

QSAM Biosciences Inc. has announced the addition of the Ellis Fischel Cancer Center as a new clinical trial site for its Phase 1 study of CycloSam® aimed at treating bone cancer. This center, recognized for its comprehensive cancer program, will assist in enrolling participants with various bone cancers. CycloSam®, a therapeutic radiopharmaceutical, targets bone tumors and aims to establish safety and efficacy signals through this open-label trial. The study highlights the high medical need for effective treatments for metastatic bone cancer, with QSAM focusing on advancing CycloSam® towards commercialization.

QSAM Biosciences (OTCQB: QSAM) will present at the Emerging Growth Conference on January 25, 2023, at 10:15 AM EST. The company focuses on developing next-generation therapeutic radiopharmaceuticals for treating bone cancer, including its lead candidate CycloSam® (Samarium-153-DOTMP). The conference allows investors to interact with executive officers, including CEO Douglas Baum. Attendees can submit questions in advance or during the session. The event will be archived for later viewing on EmergingGrowth.com and its YouTube channel. Registration is required to attend.

QSAM Biosciences (OTCQB: QSAM) provides an update on its progress and goals for 2023. The company is focused on developing CycloSam® for bone cancer treatment, which targets patients with high unmet medical needs. In 2022, QSAM received Rare Pediatric Disease Designation and dosed two patients in Phase 1 trials, showing promising early signs of safety and efficacy. Financially, they raised approximately $1.5 million while reducing liabilities by $800,000. Looking forward, QSAM aims to complete its Phase 1 trial, initiate Phase 2 studies, and secure funding through a NASDAQ uplisting to support ongoing trials.

QSAM Biosciences reported promising progress in its clinical program for CycloSam® aimed at treating metastatic bone cancer. The company dosed its second patient in a Phase 1 trial, which continues to show preliminary positive results. Financially, QSAM recorded a net loss of $1.23 million for Q3 2022, slightly up from $1.05 million in Q3 2021. Operating expenses increased marginally to $1.21 million. The company raised approximately $1 million through a private placement. Cash on hand as of September 30, 2022, was $899,290.

QSAM Biosciences has added Rutgers Cancer Institute of New Jersey as a clinical trial site for its Phase 1 study on CycloSam® (Samarium-153-DOTMP), targeting bone cancer. This trial aims to determine the maximum tolerated dose and assess early efficacy signals in patients with metastatic bone cancer. CycloSam® is believed to provide significant benefits for patients with limited treatment options. An estimated 400,000 new malignant bone metastasis cases occur annually in the U.S., presenting a substantial market need for new therapies.

QSAM Biosciences Inc. reported progress in its Phase 1 clinical trial of CycloSam® for metastatic bone cancer. Preliminary results from the first patient show promising safety and efficacy signals. The company had a 57% decrease in net loss, reporting $1.33 million for the quarter ended June 30, 2022, down from $3.07 million in the same period last year. Operating expenses also decreased to $1.26 million compared to $2.90 million. The company plans to add clinical and reactor sites in Q3 2022 and aims for a NASDAQ uplisting in early 2023 if market conditions improve.

QSAM Biosciences has received a pivotal patent from the U.S. Patent & Trademark Office for its CycloSam® radiopharmaceutical formulation. This patent safeguards the preparation method using a nonradioactive kit that enhances purity and reduces costs. The patent encompasses the use of Samarium-153 along with other isotopes, extending potential applications in treating bone tumors and performing bone marrow ablations. With a total of 14 patents, this strengthens QSAM's intellectual property portfolio, positioning CycloSam® as a promising candidate for cancer treatment.